458 Studies Now Enrolling
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Study of ION-682884 (SC) in patients with TTR Amyloidosis Polyneuropathy
| Sponsor: | Ionis Pharmaceuticals, Inc. Ionis |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAS6519 |
| U.S. Govt. ID: | NCT04136184 |
| Contact: | Jorge Cabrera or Raisy Fayerman: 212-305-6035 / jec2273@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be able to walk either with or without help.
This study is closed
Do You Qualify?
| Are you between 18 and 82 years old? | Yes | No |
| Are you willing to use contraceptive methods and are you non-pregnant and non-lactating? | Yes | No |
| Do you ambulate with or without assistance? | Yes | No |
| Do you have a diagnosis of hereditary transthyretin-mediated polyneuropathy? | Yes | No |
| Are you willing to adhere to vitamin A supplementation? | Yes | No |